

Clinical Trial Protocol

Iranian Registry of Clinical Trials

31 May 2026

Effect of daily consumption of probiotic yogurt on liver enzymes steatosis and fibrosis in patients with nonalcoholic fatty liver disease

Protocol summary

Study aim

If appropriate, it is recommended to use probiotic yogurt in the diet of patients with non-alcoholic fatty liver

Design

A clinical trial with a control group, parallel group, randomized groups, on 68 patients. Lottery container was used for randomization.

Settings and conduct

A controlled clinical trial will be performed at the Gastroenterology Clinic. Before the intervention, anthropometric indices, blood pressure, liver enzymes, glycemic index, insulin resistance, hepatic steatosis, liver fibrosis and lipid profile will be evaluated in all subjects. Individuals will be randomly divided into intervention and non-intervention groups. Intervention: 300 g daily probiotic yogurt for 12 weeks, control: 300 g normal yogurt daily for 12 weeks. The yogurts have the same color, shape, taste and smell are used so that the researcher and the patient are not aware of its type and only our distributor is aware of its type.

Participants/Inclusion and exclusion criteria

1. Patients with non-alcoholic fatty liver disease, 2. Aged 18-65 years, 3. Body mass index between 25-35 kg/m². 4. Patients have a fixed plan for medication use during the last 3 months.

Intervention groups

Intervention: daily 300g probiotic yogurt for 12 weeks, control: 300g normal yogurt for 8 weeks

Main outcome variables

Steatosis, fibrosis and liver enzymes including ALT, AST and GGT.

General information

Reason for update

Recruitment start date delayed due to Covid-19 pandemic and changed to December 2021.

Acronym

IRCT registration information

IRCT registration number: **IRCT20210201050210N1**

Registration date: **2021-04-19, 1400/01/30**

Registration timing: **prospective**

Last update: **2021-06-21, 1400/03/31**

Update count: **1**

Registration date

2021-04-19, 1400/01/30

Registrant information

Name

Sara Ebrahimi-Mousavi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 51 3761 3287

Email address

s-ebrahimim@razi.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-12-06, 1400/09/15

Expected recruitment end date

2022-01-05, 1400/10/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of daily consumption of probiotic yogurt on liver enzymes steatosis and fibrosis in patients with nonalcoholic fatty liver disease

Public title

Effect of daily consumption of probiotic yogurt in patients with non-alcoholic fatty liver

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Non-alcoholic fatty liver disease was approved by a gastroenterologist using fibroscan examination
Individuals aged 20 to 60 years
Patients have a fixed plan for medication use during the last 3 months
Body mass index between 25 to 35 kg/m²

Exclusion criteria:

Smokers
History of alcohol consumption
Adherence to a special diet in the last 3 months
Pregnant or lactating women or those planning to get pregnant in the next three months
Menopausal women
Individuals with pathologic conditions affecting the liver, including acute and chronic hepatitis, viral hepatitis, liver transplantation, autoimmune hepatitis, hemochromatosis, primary biliary cirrhosis, Wilson's disease, antitrypsin deficiency and thyroid disease
People with lactose intolerance
People taking antibiotics
Patients taking medications affecting serum lipids
Individuals taking multivitamin-minerals during the previous month
Patients who have used any type of probiotic product in the last two months

Age

From **20 years** old to **60 years** old

Gender

Both

Phase

N/A

Groups that have been masked

- Participant
- Investigator

Sample size

Target sample size: **68**

Randomization (investigator's opinion)

Randomized

Randomization description

Individuals will be classified based on age(20-40/40-60), gender (male/female) and BMI (25-30/30-35) into different blocks. To do randomization, an identification code will be given to each participant, and then the codes of each two participants with the same age, gender and BMI will be poured into the lottery container. Random allocation will be done by a person who is unaware of the study. The first code will be assigned to the intervention group, the second code to the control group and so other participants will be randomly assigned to the two groups

Blinding (investigator's opinion)

Double blinded

Blinding description

The shape, appearance, packaging, color and smell of both probiotic and non-probiotic yogurts will be quite similar. In addition, the person who provides yogurts to patients is aware of the type of yogurt, but the researcher and the patient are not aware of it.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Tehran University of Medical Sciences

Street address

First Floor, Faculty of Medicine, Building No. 1, North Door of the University, POURSINA St, GHODS St, ENGHELAB St

City

Tehran

Province

Tehran

Postal code

14155-6117

Approval date

2021-01-20, 1399/11/01

Ethics committee reference number

IR.TUMS.MEDICINE.REC.1399.1006

Health conditions studied

1

Description of health condition studied

Non-alcoholic fatty liver disease

ICD-10 code

K76.0

ICD-10 code description

Fatty (change of) liver, not elsewhere classified

Primary outcomes

1

Description

Hepatic steatosis

Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

Method of measurement

Fibro-scan

2

Description

Hepatic fibrosis

Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

Method of measurement

Fibro-scan

3

Description

Liver enzyme (ALT, AST and GGT)

Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

Method of measurement

Blood sample

Secondary outcomes

1

Description

Lipid profile (TG, Total cholesterol, LDL-c and LDH-c)

Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

Method of measurement

Blood sample

2

Description

Glycemic index (FBS, FBI, HOMA-IR and QUICKI)

Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

Method of measurement

Blood sample

3

Description

Weight

Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

Method of measurement

Scales

4

Description

Waist circumference

Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

Method of measurement

Tape meter

5

Description

Body mass index (BMI)

Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

Method of measurement

Formula (weight (kilograms) divided by the squared height (meters))

Intervention groups

1

Description

Intervention group: They will receive 300g of probiotic yogurt enriched with Bifidobacterium lactis and Lactobacillus acidophilus strains daily for 12 weeks. Microbiological analyzes showed that the average colony content of both strains is 10^6 CFU / g.

Category

Rehabilitation

2

Description

Control group: Control group: 300g will receive conventional yogurt for 12 weeks

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Dr. Seyyed Moayed Alaviyan's clinic

Full name of responsible person

Sara Ebrahimi-Mousavi

Street address

No. 178, Corner of Shadab Crossroads, Above Taleghani, Sepahbod Gharani St., Ferdowsi Square

City

Tehran

Province

Tehran

Postal code

1417935840

Phone

+98 21 8890 7154

Email

alavian@thc.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Dr. Sahraeiyan

Street address

Vice Chancellor for Research and Technology, sixth floor, Central University Organization, corner of Ghods Street, Keshavarz Blvd.

City

Tehran

Province

Tehran

Postal code

1417935840

Phone

+98 21 8163 3685

Email

vcr@tums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

50

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding*empty***Country of origin****Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Sara Ebrahimi-Mousavi

Position

Master student

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street address

No. 44, Hojjatdoost Alley, Naderi St., Keshavarz Boulevard

City

Tehran

Province

Tehran

Postal code

1417613151

Phone

+98 21 8895 5975

Email

Sara.mse95@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Sara Ebrahimi-Mousavi

Position

Master student

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street address

No. 44, Hojjatdoost Alley, Naderi St., Keshavarz Boulevard

City

Tehran

Province

Tehran

Postal code

1417613151

Phone

+98 21 8895 5975

Email

sara.mse95@gmail.com

Person responsible for updating data**Contact****Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Sara Ebrahimi-Mousavi

Position

Master student

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street address

No. 44, Hojjatdoost Alley, Naderi St., Keshavarz Boulevard

City

Tehran

Province

Tehran

Postal code

1417613151

Phone

+98 21 8895 5975

Email

sara.mse95@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to

make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available